|
The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in February 2006
Bayer Diagnostics has acquired a license to for Abbott Laboratories' free PSA and tacrolimus tests for use on Bayer's ADVIA Centaur and ADVIA Centaur CP immunoassay systems. Amorfix Life Sciences and the Ontario Genomics Institute (OGI) initiated a partnership to develop a blood test for Alzheimer's disease, EP-AD, based upon Amorfix's misfolded A-beta protein fragments. Biosite and Five Prime Therapeutics entered into a collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products. FivePrime is involved in oncology, diabetes, immunology and regenerative medicine. Bruker Daltonik and the German Collection of Microorganisms and Cell Cultures formed a collaboration for the identification and classification of microorganisms from peptide and protein profiles measured by MALDI-TOF mass spectrometry. The DSMZ uses Bruker Daltonik's novel CLINPROT BioTyper system to generate protein profiles and to perform the required advanced data analysis based on its stored 14,000 cultures, representing 6,900 species from different types of microorganisms, including bacteria, yeasts and fungi. DNAPrint Genomics is developing a test for glycated CD59 as a marker of the common complications of diabetes including renal failure due to microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries. GenExel-Sein received FDA clearance to market the DUO-CARE, a device that combines a home-use blood glucose and wrist blood pressure monitor in one device. DUO-CARE will be distributed by GenExel-Sein's U.S. subsidiary, Forecare and will be sold at select drug and discount chains starting in Q2 2006. GlucoStats System is developing a non-invasive glucose monitoring system that uses a Free-Floating Optical Probe to measure glucose from the nailbed. Diffused light from the nailbed is transmitted via the same probe to a photo diode. The company is developing desktop and handheld prototypes. Instant Technologies acquired Accu-Stat Diagnostics. Accu-Stat received FDA clearance to market its line of home testing products for drugs of abuse, breath alcohol, cholesterol, and fecal occult blood tests over-the-counter. Inverness Medical Innovations acquired ACON Laboratories lateral flow immunoassay products, worldwide. As part of the deal, Inverness will acquire a newly constructed manufacturing facility in China. Coincidentally all litigation by Inverness against Acon have been dismissed. Johnson & Johnson acquired insulin delivery company Animas Corp. in a cash-for-stock transaction valued at about $518 million. Animas will operate as a stand-alone entity within its subsidiary LifeScan Inc. The acquisition allows LifeScan to enter the race for a continuous flow glucose monitor. Animas acquired its continuous glucose monitoring technology through the $10 million purchase of Cygnus in March 2005. Zyvex and Diabetech are co-developing Project cGeNI, which stands for Glucose Nanobiosensor Implant, a wireless sensor implant targeting real-time blood glucose levels in the body.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: March 2006 |
![[Page Banner Image]](images/hprods.gif){kind=small}
